IDYAIDEAYA Biosciences, Inc.

Nasdaq ideayabio.com


$ 40.53 $ -1.03 (-2.48 %)    

Friday, 17-May-2024 15:59:59 EDT
QQQ $ 451.63 $ -0.22 (-0.05 %)
DIA $ 399.76 $ 0.74 (0.19 %)
SPY $ 529.24 $ 0.76 (0.14 %)
TLT $ 91.40 $ -0.62 (-0.67 %)
GLD $ 223.63 $ 3.63 (1.65 %)
$ 40.5
$ 40.79
$ 0.00 x 0
$ 0.00 x 0
$ 40.05 - $ 41.16
$ 20.85 - $ 47.74
761,258
na
3.04B
$ 0.83
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 02-20-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-07-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-17-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-10-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-23-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-12-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-24-2020 12-31-2019 10-K
19 11-13-2019 09-30-2019 10-Q
20 08-12-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 goldman-sachs-maintains-buy-on-ideaya-biosciences-lowers-price-target-to-46

Goldman Sachs analyst Corinne Jenkins maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from...

 wedbush-reiterates-outperform-on-ideaya-biosciences-maintains-52-price-target

Wedbush analyst Robert Driscoll reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and maintains $52 price target.

 ideaya-biosciences-q1-2024-gaap-eps-053-inline

IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(0.53) per share which met the analyst consensus estimate.

 ideaya-biosciences-announces-asco-2024-oral-presentation-for-darovasertib-in-neoadjuvant-uveal-melanoma-phase-2-investigator-sponsored-study

Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024, at 9:51 AM CDTThe abstract summary will be available on Thur...

 ideaya-biosciences-has-selected-move-forward-phase-2-expansion-dose-for-ide397-monotherapy-in-mtap-deletion-squamous-non-small-cell-lung-cancer-based-on-the-adverse-event-profile-and-preliminary-clinical-efficacy

Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on AE profile an...

 citigroup-maintains-buy-on-ideaya-biosciences-raises-price-target-to-60

Citigroup analyst Yigal Nochomovitz maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $...

 btig-initiates-coverage-on-ideaya-biosciences-with-buy-rating-announces-price-target-of-55

BTIG analyst Justin Zelin initiates coverage on IDEAYA Biosciences (NASDAQ:IDYA) with a Buy rating and announces Price Targe...

 rbc-capital-maintains-outperform-on-ideaya-biosciences-raises-price-target-to-53

RBC Capital analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target f...

 ideaya-biosciences-q4-eps-052-misses-047-estimate-sales-392m-miss-884m-estimate

IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of ...

 goldman-sachs-maintains-buy-on-ideaya-biosciences-raises-price-target-to-53

Goldman Sachs analyst Corinne Jenkins maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from...

 goldman-sachs-maintains-buy-on-ideaya-biosciences-raises-price-target-to-53

Goldman Sachs analyst Corinne Jenkins maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION